N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody-Reference-Cited by-同舟云学术

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody

Published:2023-10 Issue:10 Volume:26 Page:107786
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Zibat Arne,Zhang Xiaoxiao,Dickmanns Antje,Stegmann Kim M.,Dobbelstein Adrian W.,Alachram Halima,Soliwoda Rebecca,Salinas Gabriela,Groß Uwe,Görlich Dirk,Kschischo Maik,Wollnik Bernd,Dobbelstein Matthias^ORCID

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference85 articles.

1. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies;Zhou;Signal Transduct. Target. Ther.,2021

2. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic;Hoffmann;Cell,2021

3. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus;Fischer;Sci. Transl. Med.,2022

4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients;Jayk Bernal;N. Engl. J. Med.,2022

5. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection;Journal of Virology;2024-08-29

2. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13

3. Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection;2024-05-23

4. The Tautomeric State of N⁴-Hydroxycytidine within Base-Paired RNA;ACS Central Science;2024-04-25

5. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients;Nature Communications;2024-02-23